載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$167.47
+US$1.91 · +1.15%
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
前收盤價
US$167.47
+US$1.91 · +1.15%
盤中時間採用ET。市場資料可能有所延遲。
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
日內區間
目前US$167.47
52週區間
目前US$167.47
盤中時間採用ET。市場資料可能有所延遲。
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
日內區間
目前US$167.47
52週區間
目前US$167.47
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 9.82億 USD | 7.39億 USD | 5.64億 USD | 4.5億 USD | 3.74億 USD |
| 銷貨成本 | 3.49億 USD | 2.9億 USD | 2.27億 USD | 1.56億 USD | 1.23億 USD |
| 毛利 | 6.33億 USD | 4.49億 USD | 3.37億 USD | 2.93億 USD | 2.51億 USD |
| 研究與開發 | 3.64億 USD | 3.48億 USD | 3.67億 USD | 3.74億 USD | 2.63億 USD |
| 銷售、一般及管理費用 | 7.06億 USD | 5.45億 USD | 4.51億 USD | 4.64億 USD | 3.99億 USD |
| 營業費用 | 10.7億 USD | 8.93億 USD | 9.02億 USD | 8.38億 USD | 6.62億 USD |
| 利息收入 | 3409.5萬 USD | 5369.1萬 USD | 3536.5萬 USD | 606.9萬 USD | 393萬 USD |
| 利息支出 | 389.7萬 USD | 258.1萬 USD | 257.8萬 USD | 257.7萬 USD | 257.7萬 USD |
| 折舊和攤銷 | 3973.6萬 USD | 4238.7萬 USD | 4288.1萬 USD | 3596.2萬 USD | 2227.1萬 USD |
| 營業利益 | −4.37億 USD | −4.44億 USD | −5.65億 USD | −5.44億 USD | −4.11億 USD |
| 淨利 | −4.16億 USD | −4.36億 USD | −4.79億 USD | −6.55億 USD | −4.06億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$201.4
上漲空間 20.26%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6.37億0.03%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB4.61億0.25%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK2.65億0.58%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF2.45億0.25%954億 USD0.05%US$235+0.80%
iShares Russell Mid-Cap Growth ETFIWP1.07億0.54%200.95億 USD0.23%US$143.1+1.56%
ARK Genomic Revolution ETFARKG9645.28萬4.71%15.57億 USD0.75%US$51.30+4.08%
iShares Russell Mid-Cap ETFIWR8883.11萬0.16%567.65億 USD0.18%US$109.82+0.87%
iShares Russell 1000 Growth ETFIWF7027.57萬0.05%1305.08億 USD0.18%US$127.91+0.63%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell Mid-Cap Growth ETFIWPARK Genomic Revolution ETFARKGiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
